Literature DB >> 26961354

Improved survival in HIV treatment programmes in Asia.

Nicole L De La Mata1, Nagalingeswaran Kumarasamy2, Vohith Khol3, Oon Tek Ng4, Kinh Van Nguyen5, Tuti Parwati Merati6, Thuy Thanh Pham7, Man Po Lee8, Nicolas Durier9, Matthew Law1.   

Abstract

BACKGROUND: Antiretroviral treatment (ART) for HIV-positive patients has expanded rapidly in Asia over the last 10 years. Our study aimed to describe the time trends and risk factors for overall survival in patients receiving first-line ART in Asia.
METHODS: We included HIV-positive adult patients who initiated ART between 2003-2013 (n=16,546), from seven sites across six Asia-Pacific countries. Patient follow-up was to May 2014. We compared survival for each country and overall by time period of ART initiation using Kaplan-Meier curves. Factors associated with mortality were assessed using Cox regression, stratified by site. We also summarized first-line ART regimens, CD4+ T-cell count at ART initiation, and CD4+ T-cell and HIV viral load testing frequencies.
RESULTS: There were 880 deaths observed over 54,532 person-years of follow-up, a crude rate of 1.61 (95% CI 1.51, 1.72) per 100 person-years. Survival significantly improved in more recent years of ART initiation. The survival probability at 4 years follow-up for those initiating ART in 2003-2005 was 92.1%, 2006-2009 was 94.3% and 2010-2013 was 94.5% (P<0.001). Factors associated with higher mortality risk included initiating ART in earlier time periods, older age, male sex, injecting drug use as HIV exposure and lower pre-ART CD4+ T-cell count. Concurrent with improved survival was increased tenofovir use, ART initiation at higher CD4+ T-cell counts and greater monitoring of CD4+ T-cells and HIV viral load.
CONCLUSIONS: Our results suggest that HIV-positive patients from Asia have improved survival in more recent years of ART initiation. This is likely a consequence of improvements in treatment, patient management and monitoring over time.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26961354      PMCID: PMC4980281          DOI: 10.3851/IMP3041

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  33 in total

1.  Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study.

Authors:  Fujie Zhang; Zhihui Dou; Ye Ma; Yao Zhang; Yan Zhao; Decai Zhao; Shuntai Zhou; Marc Bulterys; Hao Zhu; Ray Y Chen
Journal:  Lancet Infect Dis       Date:  2011-07       Impact factor: 25.071

2.  Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study.

Authors:  S M Hermans; F van Leth; Y C Manabe; A I M Hoepelman; J M A Lange; A Kambugu
Journal:  HIV Med       Date:  2012-02-02       Impact factor: 3.180

3.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

4.  Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.

Authors:  Soumya Swaminathan; Chandrasekaran Padmapriyadarsini; Perumal Venkatesan; Gopalan Narendran; Santhanakrishnan Ramesh Kumar; Sheik Iliayas; Pradeep A Menon; Sriram Selvaraju; Navaneetha P Pooranagangadevi; Perumal K Bhavani; Chinnaiyan Ponnuraja; Meenalochani Dilip; Ranjani Ramachandran
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

5.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

6.  Current status of HIV treatment in Asia and the Pacific region.

Authors:  Angsana Phuphuakrat; Sasisopin Kiertiburanakul; Somnuek Sungkanuparph
Journal:  Sex Health       Date:  2014-07       Impact factor: 2.706

7.  Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.

Authors:  Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

8.  Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.

Authors:  Johan van Griensven; Rony Zachariah; Freya Rasschaert; Jules Mugabo; Edi F Atté; Tony Reid
Journal:  Trans R Soc Trop Med Hyg       Date:  2009-09-03       Impact factor: 2.184

9.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

Authors: 
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

10.  Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.

Authors:  Andrew Boulle; Catherine Orrel; Richard Kaplan; Gilles Van Cutsem; Matthew McNally; Katherine Hilderbrand; London Myer; Matthias Egger; David Coetzee; Gary Maartens; Robin Wood
Journal:  Antivir Ther       Date:  2007
View more
  16 in total

1.  Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.

Authors:  Nicole L De La Mata; Penh S Ly; Oon T Ng; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Annette H Sohn; Matthew G Law; Nagalingeswaran Kumarasamy
Journal:  Int J STD AIDS       Date:  2017-03-21       Impact factor: 1.359

2.  HIV and Aging: Demographic Change in the Asia-Pacific Region.

Authors:  Rainer Puhr; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Thuy Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Matthew G Law
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731

3.  Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.

Authors:  Rimke Bijker; Sasisopin Kiertiburanakul; Nagalingeswaran Kumarasamy; Sanjay Pujari; Ly P Sun; Oon T Ng; Man P Lee; Jun Y Choi; Kinh V Nguyen; Yu J Chan; Tuti P Merati; Do D Cuong; Jeremy Ross; Awachana Jiamsakul
Journal:  Antivir Ther       Date:  2020

4.  Growing challenges for HIV programmes in Asia: clinic population trends, 2003-2013.

Authors:  Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Man Po Lee; Cuong Duy Do; Jun Yong Choi; Jeremy L Ross; Matthew G Law
Journal:  AIDS Care       Date:  2017-01-29

5.  Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE).

Authors:  Rosario Martinez-Vega; Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Kinh Van Nguyen; Tuti P Merati; Thi Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Oon Tek Ng
Journal:  Antivir Ther       Date:  2018

6.  Loss to Follow-up Trends in HIV-Positive Patients Receiving Antiretroviral Treatment in Asia From 2003 to 2013.

Authors:  Nicole L De La Mata; Penh S Ly; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Jeremy Ross; Matthew G Law; Oon T Ng
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731

7.  Diabetes, mortality and glucose monitoring rates in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD-LITE) study.

Authors:  R Bijker; N Kumarasamy; S Kiertiburanakul; S Pujari; L Penh Sun; O T Ng; M P Lee; J Y Choi; K V Nguyen; Y J Chan; T P Merati; C D Do; J Ross; M Law
Journal:  HIV Med       Date:  2019-07-23       Impact factor: 3.180

8.  Treatment modification after second-line failure among people living with HIV in the Asia-Pacific.

Authors:  Awachana Jiamsakul; Iskandar Azwa; Fujie Zhang; Evy Yunihastuti; Rossana Ditangco; Nagalingeswaran Kumarasamy; Oon Tek Ng; Yu-Jiun Chan; Penh Sun Ly; Jun Yong Choi; Man-Po Lee; Sanjay Pujari; Sasisopin Kiertiburanakul; Romanee Chaiwarith; Tuti Parwati Merati; Shashikala Sangle; Suwimon Khusuwan; Benedict Lh Sim; Anchalee Avihingsanon; Cuong Duy; Junko Tanuma; Jeremy Ross; Matthew Law; Treat Asia Hiv Observational Database Of IeDEA Asia-Pacific
Journal:  Antivir Ther       Date:  2020

9.  HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia-Pacific region: a longitudinal cohort study.

Authors:  Win Min Han; Awachana Jiamsakul; Nur Afiqah Mohd Salleh; Jun Yong Choi; Bui Vu Huy; Evy Yunihastuti; Cuong Duy Do; Tuti P Merati; Yasmin M Gani; Sasisopin Kiertiburanakul; Fujie Zhang; Yu-Jiun Chan; Man-Po Lee; Romanee Chaiwarith; Oon Tek Ng; Suwimon Khusuwan; Rossana Ditangco; Nagalingeswaran Kumarasamy; Shashikala Sangle; Jeremy Ross; Anchalee Avihingsanon
Journal:  J Int AIDS Soc       Date:  2021-05       Impact factor: 6.707

10.  Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV.

Authors:  W M Han; A Jiamsakul; J Jantarapakde; E Yunihastuti; J Y Choi; R Ditangco; R Chaiwarith; L P Sun; S Khusuwan; T P Merati; C D Do; I Azwa; M-P Lee; K Van Nguyen; Y-J Chan; S Kiertiburanakul; O T Ng; J Tanuma; S Pujari; F Zhang; Y M Gani; S Sangle; J Ross; N Kumarasamy
Journal:  HIV Med       Date:  2020-11-17       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.